The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome in Oocyte Donors.

Trial Profile

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome in Oocyte Donors.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2013

At a glance

  • Drugs Cetrorelix (Primary)
  • Indications Ovarian hyperstimulation syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top